Posting another win for its triple G agonist, Eli Lilly and Co. rolled out top-line phase III data from Triumph-1 showing that all doses of retatrutide met primary and key secondary endpoints for obesity, with participants losing on average between 19% and 28.3% of body weight and significantly improving their cardiovascular risk factors. Read More
Infex Therapeutics Ltd. has published positive phase IIa data for its lead program, RESP-X, in the treatment of exacerbations of chronic respiratory infections caused by Pseudomonas aeruginosa and is now laying the ground for phase IIb development, after raising £4.3 million (US$5.8 million) in new capital. Read More
Antimicrobial-focused Tennor Therapeutics Ltd. will debut in Hong Kong May 22, having priced a HK$626.84 million (US$80 million) IPO. The Suzhou, China-based biotech is waiting on China’s National Medical Products Administration approval of lead asset rifasutenizol (TNP-2198), which has potential to become the first targeted combination regimen to treat H. pylori infection. Read More
Artificial intelligence, remote monitoring and need-based innovation are beginning to reshape Australia’s medtech sector’s devices, as well as the way health care itself is delivered, according to speakers at the 2026 Ausmedtech conference in Perth May 19-20. Read More
As interests and competition in the intravascular lithotripsy (IVL) market heats up, Shockwave Medical Inc. said it believes that its latest coronary IVL catheter, the C2 Aero, and other projects in the pipeline, will help it to maintain its leadership in calcium modification. Read More
Biopharma stocks, as measured on the BioWorld Biopharmaceutical Index, underperformed both the Nasdaq Biotechnology Index and the Dow Jones Industrial Average through the first four months of 2026. Read More
Researchers at UCLA have shown that divergent neuronal signaling in fragile X mice converges on EPAC2, a druggable target whose inhibition restores circuit activity and alleviates core behavioral impairments. Read More
New hires and promotions in the biopharma and med-tech industries, including: Amgen, Antengene, Blossomhill, Chiesi, Conmed, Corvista, Cytoagents, Delphi, Inmode, Invenra, Jenavalve, Predicta, Route 92. Read More
Biopharma and med-tech companies raising money in public or private financings, including: Annovis, Avricore, Co-Diagnostics, Neurosoft, Oorja Bio, Parabilis, Proencia, Regeneron, Resverlogix. Read More
Clinical updates for biopharma and med tech, including data readouts and publications: Achieve Life Sciences, Altesa, Alzinova, Ipsen, Monopar, Oncopeptides, Oorja, Pfizer, Remepy, Roivant, Savara, Savara, Skye, UCB. Read More
Biopharma and med-tech happenings, including deals and partnerships, and other news in brief: Discovery Life Sciences, Eli Lilly, Engage, Eton, Jupiter, Knight, Medtronic, Pharmala, SPR. Read More
Regulatory snapshots for biopharma and med tech, including global submissions and approvals, and other regulatory decisions and designations: Diasorin, Guardant, Immunitybio, Implantica. Read More
